INSUBCONTINENT EXCLUSIVE:
Independent analyst Kunal Bothra has a buy call on Glenmark Pharmaceuticals Ltd
with a target price of Rs 715
The current market price of Glenmark Pharmaceuticals Ltd
Time period given by the analyst is Intra Day when Glenmark Pharmaceuticals Ltd
price can reach defined target
Kunal Bothra recommended to keep stoploss at Rs 655
Glenmark Pharmaceuticals Ltd., incorporated in 1977, is a largecap company with a market cap of Rs 19104.20 crore.
Glenmark Pharmaceuticals
key Products/Revenue Segments include Pharmaceuticals which contributed Rs 6042.06 Crore to Sales Value (93.93 % of Total Sales), Other
Operating Revenue which contributed Rs 335.83 Crore to Sales Value (5.22 % of Total Sales) and Sale of services which contributed Rs 54.00
Crore to Sales Value (0.83 % of Total Sales)for the year ending 31-Mar-2018
For the quarter ended 30-09-2018, the company has reported a Consolidated sales of Rs 2539.86 Crore, up 19.28 % from last quarter Sales of
Rs 2129.37 Crore and up 14.23 % from last year same quarter Sales of Rs 2223.44 Crore Company has reported net profit after tax of Rs 414.00
The company’s top management includes Dr.Brian W Tempest, Mr.Bernard Munos, Mr.D R Mehta, Mr.Glenn Saldanha, Mr.Julio Ribeiro, Mr.Milind
Sarwate, Mr.Rajesh V Desai, Mr.Sridhar Gorthi, Mr.V S Mani, Mrs.B E Saldanha, Mrs.Cherylann Pinto
Company has Walker, Chandiok Co.LLP as its auditoRs As on 30-09-2018, the company has a total of 282,168,156 shares outstanding.
